Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed net purchases of 272,045 ordinary shares on 17 September 2026. It bought 342,142 shares at 281.50p-281.75p and sold 70,097 shares at 281.75p. The Rule 8.5 disclosure reported no derivative dealings, indemnities, options, or other arrangements.

Analysis

This is broker client-facilitation flow, not informed proprietary accumulation or a signal of offer probability. The gross purchase imbalance is only meaningful if it persists across subsequent Rule 8 disclosures and is accompanied by rising volume, a tightening discount to the implied transaction value, or changes in disclosed positions by merger-arbitrage holders. In isolation, it should not alter an AMS investment view.

Near term, repeated intermediary demand can modestly reduce freely available stock and support the trading price around the prevailing execution range, but the same inventory can be unwound quickly once client flow reverses. The relevant 1-3 month catalyst remains a formal change in transaction terms, timetable, financing certainty, or regulatory condition—not daily EPT disclosures. A widening of the deal spread on no fundamental news would be more actionable as a liquidity/positioning signal than this filing.

Contrarian consideration: market participants often overread positive net dealing by an adviser as an indication of deal confidence. Recognised intermediary status exists specifically to separate market-making activity from investment intent; treating it as directional creates adverse-selection risk. There is no standalone trade from this disclosure, and options are unlikely to offer efficient expression absent verified liquidity and a known completion timetable.

Key Decisions for Investors

• No new directional AMS position based solely on this filing; classify as routine technical flow and revisit only if similar net purchases persist for 3-5 dealing sessions alongside above-average market volume.
• For any existing AMS merger-arbitrage exposure, monitor the cash spread to the announced/implied consideration daily; reduce exposure if the spread widens materially without a sector-wide risk-off explanation, as that would indicate rising execution or approval risk.
• Create an event alert for formal offer-document publication, financing updates, Takeover Panel timetable revisions, or competition/regulatory developments. These events—not intermediary inventory—can reprice expected completion probability over the next 1-3 months.
• Falsify any flow-support thesis if subsequent Rule 8.5 filings show net sales or the shares break below the disclosed execution range on elevated volume; that would indicate the broker's facilitated inventory is being distributed rather than absorbed.